ICD-10 Coding for Fibrocystic Changes(D24.1, D24.1U, N60.19)
Learn about ICD-10 coding for fibrocystic changes, including documentation requirements, code relationships, and common pitfalls.
Complete code families applicable to Fibrocystic Changes
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| N60.19 | Diffuse cystic mastopathy of unspecified breast | Use when documenting diffuse fibrocystic changes without atypical hyperplasia. |
|
| N60.29 | Fibrocystic disease of breast with apocrine metaplasia | Use when apocrine metaplasia is documented. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutFibrocystic Changes
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Fibrocystic Changes.
Failure to document laterality
Impact
Clinical: Inaccurate clinical records., Regulatory: Potential audit issues., Financial: Denied claims due to unspecified coding.
Mitigation
Always specify left, right, or bilateral., Use templates that prompt for laterality.
Using N60.19 for pediatric patients
Impact
Reimbursement: Incorrect coding may lead to denied claims., Compliance: Non-compliance with age-specific coding guidelines., Data Quality: Inaccurate patient records.
Mitigation
Use N64.89 for patients under 18 years.
Unspecified laterality
Impact
Using unspecified codes when laterality is not documented.
Mitigation
Implement documentation templates that require laterality.